Discipline of Orthodontics and Paediatric Dentistry, Faculty of Dentistry, National University of Singapore, Singapore, Singapore.
Paediatric Dentistry, School of Dentistry, University of Leeds, Leeds, UK.
Int J Paediatr Dent. 2018 Jul;28(4):347-360. doi: 10.1111/ipd.12363. Epub 2018 Apr 10.
Over the last few years, numerous reviews and studies have awarded articaine hydrochloride local anaesthetic (LA) a superior reputation, with outcomes of different studies demonstrating a general tendency for articaine hydrochloride to outperform lidocaine hydrochloride for dental treatment. Nevertheless, there seems to be no clear agreement on which LA solution is more efficacious in dental treatment for children. There is no previous publication systematically reviewing and summarising the current best evidence with respect to the success rates of LA solutions in children.
To evaluate the available evidence on the efficacy of lidocaine and articaine, used in paediatric dentistry.
A systematic search was conducted on Cochrane CENTRAL Register of Controlled Trials, MEDLINE (OVID; 1950 to June 2017), Cumulative Index to Nursing and Allied Health Literature (CINAHL; EBSCOhost; 1982 to June 2017), EMBASE (OVID; 1980 to June 2017), SCI-EXPANDED (ISI Web of Knowledge; 1900 to June 2017), key journals, and previous review bibliographies through June 2017. Original research studies that compared articaine with lidocaine for dental treatment in children were included. Methodological quality assessment and assessment of risk of bias were carried out for each of the included studies.
Electronic searching identified 525 publications. Following the primary and secondary assessment process, six randomised controlled trials (RCT) were included in the final analysis. There was no difference between patient self-reported pain between articaine and lidocaine during treatment procedures (SMD = 0.06, P-value = 0.614), and no difference in the occurrence of adverse events between articaine and lidocaine injections following treatment in paediatric patients (RR = 1.10, P-value = 0.863). Yet, patients reported significantly less pain post-procedure following articaine injections (SMD = 0.37, P-value = 0.013). Substantial heterogeneity was noted in the reporting of outcomes among studies, with the overall quality of majority of studies being at high risk of bias.
There is low quality evidence suggesting that both articaine as infiltration and lidocaine IAD nerve blocks presented the same efficacy when used for routine dental treatments, with no difference between patient self-reported pain between articaine and lidocaine during treatment procedures. Yet, significantly less pain post-procedure was reported following articaine injections. There was no difference in the occurrence of adverse events between articaine and lidocaine injections following treatment in paediatric patients.
在过去的几年中,许多评论和研究都给予了盐酸阿替卡因局部麻醉剂(LA)较高的评价,不同研究的结果表明,盐酸阿替卡因在牙科治疗中总体上优于盐酸利多卡因。然而,对于哪种 LA 溶液在儿童牙科治疗中更有效,似乎尚无明确共识。以前没有出版物系统地综述和总结 LA 溶液在儿童中的成功率方面的现有最佳证据。
评估在儿科牙科中使用利多卡因和阿替卡因的疗效。
系统检索了 Cochrane 对照试验中心注册库、MEDLINE(OVID;1950 年至 2017 年 6 月)、护理与联合健康文献累积索引(CINAHL;EBSCOhost;1982 年至 2017 年 6 月)、EMBASE(OVID;1980 年至 2017 年 6 月)、科学引文索引扩展版(ISI Web of Knowledge;1900 年至 2017 年 6 月)、主要期刊和 2017 年 6 月之前的综述文献。纳入了比较儿童牙科治疗中阿替卡因与利多卡因的原始研究。对纳入的每项研究均进行了方法学质量评估和偏倚风险评估。
电子检索共确定了 525 篇文献。经过初步和二次评估过程,最终分析纳入了 6 项随机对照试验(RCT)。在治疗过程中,患者自我报告的疼痛方面,阿替卡因和利多卡因之间没有差异(SMD = 0.06,P 值 = 0.614),在儿童患者治疗后,阿替卡因和利多卡因注射后不良反应的发生也没有差异(RR = 1.10,P 值 = 0.863)。然而,患者报告在阿替卡因注射后,术后疼痛明显减轻(SMD = 0.37,P 值 = 0.013)。研究结果的报告存在很大的异质性,大多数研究的整体质量存在高度偏倚风险。
有低质量证据表明,阿替卡因浸润和利多卡因 IAD 神经阻滞在常规牙科治疗中同样有效,在治疗过程中,患者自我报告的疼痛方面,阿替卡因和利多卡因之间没有差异。然而,阿替卡因注射后报告的疼痛明显减轻。在儿童患者治疗后,阿替卡因和利多卡因注射后不良反应的发生也没有差异。